Aldoxorubicin

Aldoxorubicin is a drug compound in clinical trials being researched by CytRx Pharmaceuticals.

References

Kratz, F; Azab, S; Zeisig, R; Fichtner, I; Warnecke, A (Jan 2013). "Evaluation of combination therapy schedules of doxorubicin and an acid-sensitive albumin-binding prodrug of doxorubicin in the MIA PaCa-2 pancreatic xenograft model". Int J Pharm. 441 (1-2): 499–506. doi:10.1016/j.ijpharm.2012.11.003. PMID 23149257.
Walker, L; Perkins, E; Kratz, F; Raucher, D (Oct 2012). "Cell penetrating peptides fused to a thermally targeted biopolymer drug carrier improve the delivery and antitumor efficacy of an acid-sensitive doxorubicin derivative". Int J Pharm. 436 (1-2): 825–32. doi:10.1016/j.ijpharm.2012.07.043. PMID 22850291.
Kratz, F; Warnecke, A (Dec 2012). "Finding the optimal balance: challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems". J Control Release. 164 (2): 221–35. doi:10.1016/j.jconrel.2012.05.045. PMID 22705248.
Sanchez, E; Li, M; Wang, C; Nichols, CM; Li, J; Chen, H; Berenson, JR (Jul 2012). "Anti-myeloma effects of the novel anthracycline derivative INNO-206". Clin Cancer Res. 18 (14): 3856–67. doi:10.1158/1078-0432.CCR-11-3130. PMID 22619306.

This article is issued from Wikipedia - version of the 12/8/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.